PSA-based prostate cancer screening reduces mortality but increases diagnoses
New review shows prostate cancer screening might save lives but also finds more diagnoses
This meta-analysis of six randomized trials with 789,086 men in Europe and North America found PSA screening likely reduces prostate cancer-…
A large study of nearly eight hundred thousand men found that checking for prostate cancer with blood tests likely lowers death rates from t…
Robot-assisted distal pancreatectomy reduces blood loss and conversions but increases operative time and cost
Robot Surgery Matches Laparoscopic for Pancreas Cancer Outcomes
This systematic review and meta-analysis of 15790 patients undergoing distal pancreatectomy found that robot-assisted distal pancreatectomy …
New data shows robot-assisted pancreas surgery matches standard laparoscopic methods in safety and cancer control, while cutting blood loss …
Narrative review of adoptive cell therapies for solid tumors and their challenges
New Cell Therapy Finally Reaches Stubborn Solid Tumors
This narrative review synthesizes evidence on adoptive cell therapies for solid tumors, including CAR-T, TIL, and TCR-T approaches. The auth…
• Cell therapy now shows real promise against solid cancers like lung or breast • Patients with hard-to-treat tumors may gain new options so…
Systematic review and meta-analysis on immunotherapy for head and neck squamous cell carcinoma
Immunotherapy helps advanced head and neck cancer patients live longer
This systematic review and meta-analysis synthesized evidence on immunotherapy for head and neck squamous cell carcinoma. The authors report…
New analysis shows immune therapy helps advanced head and neck cancer patients survive longer when combined with other treatments
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Narrative review on emergency colorectal cancer management in patients aged 80 years and older
Older patients with emergency colon cancer need geriatric care plans now
This narrative review synthesizes management strategies for emergency colorectal cancer in patients aged 80 years and older. It finds that b…
Most colon cancers in people over 80 cause emergencies that demand special geriatric care plans to save lives and preserve function
Review of glioma organoid models for mechanistic discovery and therapy development
Finally Lab-Grown Brain Models Could Speed Up Glioma Treatments
This narrative review summarizes glioma organoid model systems for studying tumor-neural interactions. It concludes these models provide a f…
• Tiny lab-grown brains mimic real tumor behavior better than old methods • Kids and adults fighting deadly brain cancers like glioblastoma …
Meta-analysis of PET/CT metabolic parameters for predicting NSCLC response after neoadjuvant therapy
New Scan Trick Spots Lung Cancer Treatment Success Weeks Earlier
This meta-analysis synthesized evidence on 18F-FDG PET/CT metabolic parameters for predicting major pathological response in non-small cell …
• Scans show if chemo shrinks tumors before surgery • Helps patients avoid unnecessary risky operations • Hospitals need more testing before…
FDA Approves Ziextenzo (pegfilgrastim-bmez) for Febrile Neutropenia and Acute Radiation Syndrome
FDA approves new biosimilar drug Ziextenzo to prevent infections in cancer patients.
The FDA approved Ziextenzo (pegfilgrastim-bmez) to decrease febrile neutropenia in patients with non-myeloid malignancies receiving myelosup…
The FDA approved Ziextenzo, a biosimilar to Neulasta, to prevent infections in cancer patients receiving chemotherapy and to treat radiation…
FDA Approves Abiraterone Acetate (Yonsa) for Metastatic Castration-Resistant Prostate Cancer
FDA approves new prostate cancer drug Yonsa to slow tumor growth.
The FDA approved abiraterone acetate (Yonsa) in combination with methylprednisolone for metastatic castration-resistant prostate cancer. The…
The FDA approved Yonsa (abiraterone acetate) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy…
FDA Approves Tecentriq Hybreza (atezolizumab/hyaluronidase) for Multiple Cancers
FDA approves new shot form of cancer drug Tecentriq Hybreza
The FDA approved Tecentriq Hybreza, a subcutaneous formulation of atezolizumab with hyaluronidase, for multiple indications including NSCLC,…
The FDA approved Tecentriq Hybreza, a new injectable form of the cancer drug atezolizumab, for several types of cancer including lung cancer…
FDA Approves Tecentriq (atezolizumab) for Alveolar Soft Part Sarcoma
FDA approves first drug for rare soft tissue sarcoma in children and adults.
The FDA approved Tecentriq (atezolizumab) for adult and pediatric patients 2 years and older with unresectable or metastatic alveolar soft p…
The FDA approved Tecentriq for alveolar soft part sarcoma (ASPS), a rare cancer that often spreads. This is the first treatment specifically…